Foghorn Therapeutics Therapeutic Compounds Patent Publication

The European Patent Office has published patent application EP4709726A1 by Foghorn Therapeutics Inc. for therapeutic compounds. The publication includes details on the applicants, inventors, and International Patent Classification codes related to the compounds and their uses.

Mirati Therapeutics Files Patent for Substituted Quinoxalines

The European Patent Office has published patent application EP4709714A1 filed by Mirati Therapeutics, Inc. for substituted quinoxalines. This publication relates to potential new therapeutic compounds.

EPO Patent for Prostaglandin Modulators

The European Patent Office has published a patent application (EP4709481A1) for bicyclic alcohols and ethers designed as prostaglandin modulators. The patent was applied for by Amgen Inc. and lists multiple inventors.

EPO Patent Application EP4709707A1: NMDA Receptor Antagonists

The European Patent Office has published patent application EP4709707A1 concerning antagonists of N-methyl-D-aspartate receptors and their use. The application was filed by Fakultní Nemocnice Hradec Králové and Ustav Experimentalni Mediciny Akademie Ved Cr, v.v.i. and lists several inventors.

EPO Patent: Pyrazoloquinazoline Derivatives for G12D Mutant KRAS Cancer Treatment

The European Patent Office has published patent application EP4709729A1 concerning pyrazoloquinazoline derivatives for treating G12D mutant KRAS cancer. The patent was filed by Jazz Pharmaceuticals Ireland Ltd. and lists specific inventors.

EPO Patent EP4709353A1: Injectable Sustained Release Buprenorphine Formulation

The European Patent Office has published patent application EP4709353A1 concerning an injectable sustained-release buprenorphine formulation. The patent application lists Michael Guarnieri as both the applicant and inventor. This publication is part of the EPO's regular bulletin for therapeutic innovations.

EPO Patent Publication EP4709388A1: Inhibitor of Megakaryocyte Differentiation

The European Patent Office has published patent application EP4709388A1 by Otsuka Pharmaceutical Co., Ltd. The patent relates to an inhibitor of megakaryocyte differentiation and maturation. The publication date is March 18, 2026.

EPO Patent: Isoxazolidines as Ripk1 Inhibitors

The European Patent Office has published patent application EP4709723A1 concerning isoxazolidines as Ripk1 inhibitors for therapeutic use, filed by Genzyme Corporation. This publication details a new potential therapeutic compound and its application.

Isoxazolidines as Ripk1 Inhibitors Patent Publication

The European Patent Office has published patent application EP4709716A1 concerning isoxazolidines as Ripk1 inhibitors. The publication lists Genzyme Corporation as the applicant and details various inventors and IPC classifications related to pharmaceutical compounds and their therapeutic uses.

Isoxazolidines as RIPK1 Inhibitors for Therapeutic Use

The European Patent Office has published patent application EP4709722A1 concerning isoxazolidines as RIPK1 inhibitors for therapeutic use, filed by Genzyme Corporation. This publication details potential new therapeutic agents and their applications.